Stock Ticker

  • Loading stock data...

Novavax, Inc (NASDAQ:NVAX) Chooses Australia For Its COVID-19 Clinical Trials

The deadly COVID-19 pandemic continues to affect lives globally, with many people hardly affording to pay their house rent. It is frustrating that until no scientific cure to help handle the condition has been established yet. However, any good efforts mean a lot to frustrated people globally. There are reports about another candidate that is […]

Novavax, Inc. (NASDAQ:NVAX) Shares Fall On RSV, NanoFlu Vaccine Updates

At the star of this year, analysts predicted that investors in Novavax, Inc. (NASDAQ:NVAX) would be keenly watching for any update in December that could give any signal the future of Gaithersburg biotech. On the contraly, investors got a different announcement. The company’s shares went down by 22% on Tuesday. This was triggered by the […]

The Preclinical Influenza Nanoparticle Study By Novavax, Inc (NASDAQ:NVAX) Published In Vaccine

The stock of Novavax, Inc (NASDAQ:NVAX) closed at $1.06 maintaining the same standing in yesterday’s trading session. This provider has today made an announcement regarding the publication of data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) in the journal Vaccine. It is directing a lot of […]

Novavax, Inc. (NASDAQ:NVAX) Announces Positive Results From Phase 2 Clinical Tests Of New RSV F Vaccine

Novavax, Inc. (NASDAQ:NVAX) recently announced positive results from the ongoing phase 2 safety and immunogenicity clinical trials of the RSV F Vaccine in older adults. The new data on the preclinical trials in older adults (E201 and E301) together with additional findings from the phase 3 clinical trials of the vaccine for infants through maternal […]

Novavax, Inc. (NASDAQ:NVAX) Publishes RSV F Protein Data In Vaccine

Novavax’s, Inc. (NASDAQ:NVAX) data from phase II trials of RSV F Vaccines that will be used in women within the age of child bearing have been published in the Vaccine Journal. The company is developing the vaccine with the aim of protecting newborns from RSV conditions. The first results from the trial were reported in […]

Novavax, Inc. (NASDAQ:NVAX) Reports $5.7 Million In Revenue In Q1 2017

Novavax, Inc. (NASDAQ:NVAX) has announced its financial results for the first quarter of 2017. In a statement, Novavax President and CEO Stanley C. Erck said the company made a lot of progress in the implementation of key clinical studies of the RSV F vaccine for maternal immunization to infants as well as for use in […]

The Failed RSV Vaccine Trial Spells Out A Cancellation Of Bonuses For Novavax, Inc (NASDAQ:NVAX)

The Gaithersburg-based Novavax, Inc (NASDAQ:NVAX) last year received a major blow after the RSV vaccine trial targeting the elderly patients it had directed much of it resources and efforts to failed to deliver the much awaited for results. Novavax latest proxy statement revealed a little more in regards to the company’s reaction.Last year, the provider had moved […]

Novavax, Inc. (NASDAQ:NVAX) Reports $-0.24/Share EPS In Q42016

Novavax, Inc. (NASDAQ:NVAX) recently reported about its Q4 2016 in September 2016. The company’s EPS or earnings per share, stood at $-0.24/Share. The collective analysts’ estimate was $-0.26/Share, which means that the $0.02 difference was found. Analysts counting on Novavax, Inc. According to the analysts, the company’s Revenue Estimates for the present quarter can be […]

Novavax, Inc. (NASDAQ:NVAX) Publishes Study for RSV-F Vaccine and Schedules Investor Meeting

Novavax, Inc. (NASDAQ:NVAX) has announced that it would be hosting its “3rd Annual Analyst and Investor conference”, on September 29, 2015 in New York. Furthermore, the company has also revealed that its guinea pig trials, focused on maternal immunization, have been observed to be highly immunogenic. The results of the study have been published in […]

Novavax, Inc. (NASDAQ:NVAX) Enrolls Pregnant Women In Second Phase Study Of RSV Vaccine

Boston, MA 10/15/2014 (wallstreetpr) – Novavax, Inc. (NASDAQ:NVAX) has initiated second phase clinical trial of its study concerning the evaluation of respiratory syncytial virus (RSV) vaccine on pregnant women. Aim Of The Study As briefed in the article, the biopharmaceutical company has started enrollment in the second phase of the RSV F-protein nanoparticle vaccine. Healthy women […]

Stock Update: Turtle Beach Corp (NASDAQ:HEAR), Novavax, Inc. (NASDAQ:NVAX), Barracuda Networks, Inc. (NYSE:CUDA)

Boston, MA 10/15/2014 (wallstreetpr) –  Turtle Beach Corp (NASDAQ:HEAR) which is an audio solutions provider for the video games industry announced on 14th October that its newly introduced “Recon 320” brand of headsets compatible with both PC and mobile handset usage is now available in retail stores and online retailers. The newly introduced product carries a […]

Novavax, Inc. (NASDAQ:NVAX) Sold 28.75 Million Shares Of Its Common Stock; Portion Of Proceeds To Be Used In Vaccine Trials

Boston, MA 06/13/2014 (wallstreetpr) – Novavax, Inc. (NASDAQ:NVAX) on June 11, 2014 said that the company sold $115 million in gross proceeds as it offered 28.75 million shares of company’s stock at a rate of $4 per share. This also includes 3.75 million shares being scooped up by the underwriters. The company said that a part […]

Novavax, Inc. (NASDAQ:NVAX) Prices Its Public Issue

Boston, MA 06/09/2014 (wallstreetpr) – A clinical-stage bio-pharmaceutical company, Novavax, Inc. (NASDAQ:NVAX) announced the pricing of its public issue of 25 million shares, which was underwritten fully. Including the option to underwriters, a total of 28.75 million shares will be allotted to the public. Pricing of Shares The company priced its 25 million shares at […]

Novavax, Inc. (NASDAQ:NVAX)’s Makes An IPO Announcement, Traders Exercise Caution

Boston, MA 06/09/2014 (wallstreetpr) – Novavax, Inc. (NASDAQ:NVAX), a bio-pharmaceutical company that works arduously on commercialization, development and discovery of vaccines and adjuvants prepared from recombinant nanoparticles, announced an offer to sell of IPO. A $100M IPO NVAX intends to sell out its common stocks worth $100 million, subject to congenial market conditions and such other […]

Novavax, Inc. (NASDAQ:NVAX): Pricing Of Public Offering

Boston, MA 06/06/2014 (wallstreetpr) – Novavax, Inc. (NASDAQ:NVAX) announced that it will bring a secondary offering of $100 million in new stock. The stocks took a hit and plunged by more than 7%. The company has announced the pricing of the public offering of 25 million shares of common stock. The underwritten public offering offered […]

Sign Up To Get Our Latest Stocks Alerts